A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Public ClinicalTrials.gov record NCT06704724. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1 OPEN-LABEL STUDY OF PF-07985045 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Study identification
- NCT ID
- NCT06704724
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 30 participants
Conditions and interventions
Interventions
- Bevacizumab Combination Product
- Carboplatin Combination Product
- Cetuximab Combination Product
- Cisplatin Combination Product
- Fluorouracil Combination Product
- Gemcitabine Combination Product
- Leucovorin Combination Product
- Nab-paclitaxel Combination Product
- Oxaliplatin Combination Product
- PF-07284892 Combination Product
- PF-07985045 Drug
- Paclitaxel Combination Product
- Pembrolizumab Combination Product
- Sasanlimab Combination Product
- pemetrexed Combination Product
Combination Product · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 9, 2024
- Primary completion
- Mar 10, 2028
- Completion
- Mar 10, 2029
- Last update posted
- Mar 12, 2026
2024 – 2029
United States locations
- U.S. sites
- 12
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Fayetteville | Arkansas | 72703 | — |
| Highlands Oncology Group | Rogers | Arkansas | 72758 | — |
| Highlands Oncology Group | Springdale | Arkansas | 72762 | — |
| City of Hope (City of Hope National Medical Center, City Of Hope Medical Center) | Duarte | California | 91010 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| DFCI Chestnut Hill | Newton | Massachusetts | 02467 | — |
| Columbia University Irving Medical Center | New York | New York | 10032 | — |
| The Trustees of Columbia University and The New York and Presbyterian Hospital | New York | New York | 10032 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison | Wisconsin | 53718 | — |
| University of Wisconsin Carbone Cancer Center-University Hospital | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06704724, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 12, 2026 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06704724 live on ClinicalTrials.gov.